NNC0662-0419 Phase 2 Trial Compares Novo Drug to Semaglutide

What the NNC0662-0419 phase 2 trial is actually testing

A clinical trial registry record posted on September 11, 2026 lists a phase 2 study of NNC0662-0419, an experimental medicine from Novo Nordisk A/S, in adults living with type 2 diabetes. The study identifier is NCT07415954, the status is recruiting, and planned enrollment is 270 participants. According to the registry entry, the purpose is to look at the effect and safety of different dose levels of the compound.

The design is randomized: participants receive either NNC0662-0419, semaglutide, or placebo, and the registry says which treatment a participant gets is decided by chance. Randomization matters because it is what allows a later comparison between groups to be treated as a fair one rather than as a reflection of who was healthier or more motivated at the start.

The registry also states plainly that NNC0662-0419 is a new medicine that cannot be prescribed by doctors, and that it has previously been tested in humans. That second phrase is the registry's way of saying earlier-stage human testing has already happened, which is the normal precondition for moving into a phase 2 dose-ranging study.

Why using semaglutide as the comparator is the notable part

Semaglutide is the active ingredient in Novo Nordisk's Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management. It is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a gut hormone that increases insulin release when blood sugar is high and slows how quickly the stomach empties. It is also, at this point, the reference standard that newer metabolic drugs are measured against.

A phase 2 trial does not have to include an active comparator. Many are placebo-controlled only, because the question at that stage is whether the compound does anything at all and which dose levels are tolerable. Including semaglutide as a third arm means the sponsor is willing to generate data on how the new molecule stacks up against an approved product it already sells — a more demanding question to ask this early.

Novo Nordisk describes semaglutide in the registry text as an approved medication for type 2 diabetes, which it is. The company has not published results from this study, and no efficacy or safety findings exist in the public record yet. The registry entry is a plan, not an outcome.

Because semaglutide is the comparator arm here, readers already on it may find the semaglutide dosage calculator useful for keeping their own records consistent while this trial plays out.

Separately, a paper in Diabetes, Obesity and Metabolism describes a GLP-1 receptor agonist designed around a two-week interval with drug-free windows intended to improve receptor homeostasis and gastrointestinal tolerability.

What the registry record does not tell you

The listing is thin in the ways that matter most to anyone trying to guess what NNC0662-0419 is. It does not state the molecular class — whether it acts on the GLP-1 receptor, on amylin, on glucagon, or on some combination. It does not state the route of administration, the dosing interval, or the number of dose arms. It does not name the primary endpoint or the trial's duration.

That absence is worth respecting rather than filling in. Development-code compounds routinely change shape between phase 1 and phase 3, and several have been quietly discontinued after dose-ranging data came back unimpressive. Until Novo Nordisk or an investigator publishes something, the honest description of NNC0662-0419 is a phase 2 candidate for type 2 diabetes with unknown mechanism.

It also cannot be obtained. The registry is explicit that this is not a prescribable medicine. Anything sold under a similar-looking research code by a non-pharmacy vendor has no connection to this trial and no established identity, purity, or safety profile.

Phase 2 studies exist largely to identify which dose levels work and are tolerable, which is the same logic behind what titration means in a provider-directed protocol.

The registry entry for the completed tirzepatide kidney disease study lists 134 participants and a duration of about 56 weeks, with no results yet posted.

How this fits the wider GLP-1 and incretin pipeline

The same week's literature shows how much of the field is now about refinement rather than first principles. A paper in Diabetes, Obesity and Metabolism describes a GLP-1 receptor agonist engineered for a two-week interval with deliberate drug-free windows, with the stated aims of improving efficacy, receptor homeostasis, and gastrointestinal tolerability. The authors are proposing that when a receptor is stimulated may matter as much as how much.

On the approved-drug side, Eli Lilly's phase 2 study of tirzepatide — the dual GIP and GLP-1 receptor agonist marketed as Mounjaro and Zepbound — in adults with overweight or obesity and chronic kidney disease, with or without type 2 diabetes, is now listed as completed. That study enrolled 134 participants across roughly 56 weeks and up to 12 visits, and its results have not been posted.

Other registry activity points the same direction: indication expansion and combination questions. An early-phase window study at UNC Lineberger is examining tirzepatide's effect on endometrial tissue before surgery in 20 patients, and separate academic trials are testing semaglutide in alcohol use disorder after bariatric surgery and in cocaine use disorder. None of these are approved uses.

If a future switch to a different molecule or dosing interval ever comes up, a consistent history built through side-effect logging is what makes the before-and-after interpretable.

Is a head-to-head phase 2 result likely to change anything soon?

Not quickly. Phase 2 dose-ranging studies of this size are designed to pick doses and flag tolerability problems, not to settle which drug is better. Even a favorable comparison against semaglutide in 270 participants would need to be reproduced in much larger phase 3 trials before it carried regulatory weight, and those trials typically run for years.

What a result could change sooner is the conversation. If a new Novo Nordisk molecule shows a different tolerability pattern or a different dosing rhythm than weekly semaglutide, that becomes the framing for every subsequent pipeline story — and, eventually, for what providers offer. That is a reason to note the trial now and check back for posted results, not a reason to expect anything in the near term.

According to the ClinicalTrials.gov record for NCT07415954, the study is recruiting 270 participants with type 2 diabetes and randomly assigns them to NNC0662-0419, semaglutide, or placebo.